BioStem Expands Wound Care Portfolio with $15M BioTissue Acquisition and $29M Revenue
BioStem acquired BioTissue's surgical and wound care business for $15M upfront plus up to $25M in regulatory and royalty milestones, adding Neox® and Clarix® lines that generated $29M in 2025 revenues. Post-closing, BioStem holds $16M in cash and promoted Barry Hassett to CCO to lead the expanded commercial organization.
1. BioStem Completes Acquisition of Surgical and Wound Care Business
On January 21, 2026, BioStem Technologies, Inc. finalized its definitive asset purchase agreement with BioTissue Holdings, Inc., acquiring the Neox® and Clarix® product lines along with the associated commercial infrastructure. The transaction terms include an upfront cash payment of approximately $15 million, plus up to $10 million in regulatory milestone payments tied to 510(k) clearance for a new product and up to $15 million in commercial royalty milestones. The acquired surgical and wound care assets generated roughly $29 million in sales in 2025.
2. Expansion of Commercial Footprint and Leadership Changes
Through this acquisition, BioStem integrates a nationwide network of direct sales representatives and independent agents, as well as key group purchasing organization contracts, significantly bolstering its hospital inpatient and outpatient reach. The company’s cash and restricted cash balance stands at approximately $16 million post–closing. Concurrently, Barry Hassett has been promoted to Chief Commercial Officer to lead the enlarged commercial organization; he brings over 25 years of industry experience, including five years with BioTissue where he launched its surgical and wound care business.
3. Strategic Rationale and Market Growth Prospects
BioStem’s entry into acute wound care and soft-tissue repair complements its existing chronic wound portfolio, creating synergies across placental and umbilical allograft platforms. Management projects positive EBITDA contributions from the acquired assets in 2026 and anticipates accelerated revenue growth driven by expanded access to major GPO networks and hospital settings. The transaction positions BioStem to target adjacent high-value segments such as burns and surgical repair, with management forecasting double-digit percentage increases in total addressable market penetration over the next two years.
4. Upcoming Investor Conference Call
BioStem will host a conference call on January 22, 2026 at 8:00 a.m. Eastern Time to discuss the acquisition and financial outlook. Investors can dial 1-877-704-4453 or 1-201-389-0920, or listen via webcast on the Events page of BioStem’s investor relations website. Management will address integration plans, 2026 guidance, and expected synergies from the newly combined commercial team.